Repare Therapeutics Inc. (RPTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a lack of $0.35. This compares to a lack of $0.81 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of +100.00%. 1 / 4 in the past, it was anticipated that this firm would put up a lack of $0.56 per share when it really produced a lack of $0.39, delivering a shock of +30.36%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates thrice.
Repare Therapeutics, which belongs to the Zacks Medical – Biomedical and Genetics trade, posted revenues of $11.62 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 132.40%. This compares to zero revenues a 12 months in the past.
The sustainability of the inventory’s rapid value motion primarily based on the recently-released numbers and future earnings expectations will largely rely on administration’s commentary on the earnings name.
Repare Therapeutics shares have added about 29% for the reason that starting of the 12 months versus the S&P 500’s achieve of 14.6%.
What’s Subsequent for Repare Therapeutics?
Whereas Repare Therapeutics has outperformed the market to date this 12 months, the query that involves buyers’ minds is: what’s subsequent for the inventory?
There aren’t any simple solutions to this key query, however one dependable measure that may assist buyers deal with that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but in addition how these expectations have modified these days.
Empirical analysis reveals a robust correlation between near-term inventory actions and traits in earnings estimate revisions. Traders can monitor such revisions by themselves or depend on a tried-and-tested ranking software just like the Zacks Rank, which has a formidable monitor document of harnessing the facility of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for Repare Therapeutics was favorable. Whereas the magnitude and path of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #2 (Purchase) for the inventory. So, the shares are anticipated to outperform the market within the close to future. You possibly can see the whole record of as we speak’s Zacks #1 Rank (Sturdy Purchase) shares right here.
Will probably be attention-grabbing to see how estimates for the approaching quarters and the present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.29 on $5 million in revenues for the approaching quarter and -$1.73 on $20 million in revenues for the present fiscal 12 months.
Traders ought to be aware of the truth that the outlook for the trade can have a cloth affect on the efficiency of the inventory as effectively. When it comes to the Zacks Trade Rank, Medical – Biomedical and Genetics is at present within the prime 36% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
LifeMD, Inc. (LFMD), one other inventory within the broader Zacks Medical sector, has but to report outcomes for the quarter ended September 2025. The outcomes are anticipated to be launched on November 17.
This firm is predicted to put up quarterly lack of $0.06 per share in its upcoming report, which represents a year-over-year change of +57.1%. The consensus EPS estimate for the quarter has remained unchanged over the past 30 days.
LifeMD, Inc.’s revenues are anticipated to be $62.3 million, up 16.7% from the year-ago quarter.
Ought to You Put money into Repare Therapeutics Inc. (RPTX)?
Earlier than you spend money on Repare Therapeutics Inc. (RPTX), wish to know one of the best shares to purchase for the following 30 days? Take a look at Zacks Funding Analysis for our free report on the 7 finest shares to purchase.
Zacks Funding Analysis has been dedicated to offering buyers with instruments and unbiased analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a mean achieve of +24.08% per 12 months. (These returns cowl a interval from January 1, 1988 by Could 6, 2024.)
Repare Therapeutics Inc. (RPTX) : Free Inventory Evaluation Report
LifeMD, Inc. (LFMD) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
